KR20150084862A - 면역조절용 사퀴나비어-no - Google Patents

면역조절용 사퀴나비어-no Download PDF

Info

Publication number
KR20150084862A
KR20150084862A KR1020157013049A KR20157013049A KR20150084862A KR 20150084862 A KR20150084862 A KR 20150084862A KR 1020157013049 A KR1020157013049 A KR 1020157013049A KR 20157013049 A KR20157013049 A KR 20157013049A KR 20150084862 A KR20150084862 A KR 20150084862A
Authority
KR
South Korea
Prior art keywords
saq
disease
cells
autoimmune
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157013049A
Other languages
English (en)
Korean (ko)
Inventor
페르디난도 니콜레티
Original Assignee
온코녹스 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코녹스 에이피에스 filed Critical 온코녹스 에이피에스
Publication of KR20150084862A publication Critical patent/KR20150084862A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157013049A 2012-11-20 2013-11-20 면역조절용 사퀴나비어-no Withdrawn KR20150084862A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728330P 2012-11-20 2012-11-20
US61/728,330 2012-11-20

Publications (1)

Publication Number Publication Date
KR20150084862A true KR20150084862A (ko) 2015-07-22

Family

ID=49759262

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157013049A Withdrawn KR20150084862A (ko) 2012-11-20 2013-11-20 면역조절용 사퀴나비어-no

Country Status (11)

Country Link
US (1) US20150283127A1 (cg-RX-API-DMAC7.html)
EP (1) EP2922545B1 (cg-RX-API-DMAC7.html)
JP (1) JP6283680B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150084862A (cg-RX-API-DMAC7.html)
CN (1) CN104822379B (cg-RX-API-DMAC7.html)
AU (1) AU2013349804A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015011299A2 (cg-RX-API-DMAC7.html)
CA (1) CA2891771A1 (cg-RX-API-DMAC7.html)
IL (1) IL238866A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015006249A (cg-RX-API-DMAC7.html)
WO (1) WO2014079868A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104127858A (zh) * 2014-07-26 2014-11-05 滨州医学院 甲磺酸沙奎拉韦在制备预防或治疗内毒素血症和脓毒症的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003674T2 (tr) * 1998-06-09 2001-07-23 J. Embro William Epidermal iltihapların ve enfeksiyonların tedavisine yönelik metot.
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
US20030138423A1 (en) * 2001-12-14 2003-07-24 Cedars-Sinai Medical Center Method of treating inflammation with HIV-1 protease inhibitors and their derivatives
HRP20140929T1 (hr) * 2008-08-01 2014-12-05 Onconox Aps Antitumorska svojstva no-modificiranih inhibitora proteaze
WO2012088305A1 (en) * 2010-12-22 2012-06-28 The Feinstein Institute For Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors

Also Published As

Publication number Publication date
JP2015537023A (ja) 2015-12-24
WO2014079868A1 (en) 2014-05-30
IL238866A0 (en) 2015-06-30
CN104822379A (zh) 2015-08-05
JP6283680B2 (ja) 2018-02-21
US20150283127A1 (en) 2015-10-08
MX2015006249A (es) 2015-12-03
EP2922545B1 (en) 2016-09-21
CN104822379B (zh) 2017-08-25
HK1212895A1 (zh) 2016-06-24
EP2922545A1 (en) 2015-09-30
CA2891771A1 (en) 2014-05-30
AU2013349804A1 (en) 2015-06-04
BR112015011299A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
Jager et al. The kinase inhibitory region of SOCS-1 is sufficient to inhibit T-helper 17 and other immune functions in experimental allergic encephalomyelitis
Wang et al. Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells
US8454967B2 (en) Compositions and methods for modulating the immune system
Gao et al. Artemisinins: promising drug candidates for the treatment of autoimmune diseases
ES2198163T3 (es) Composicion destinada a la prevencion y tratamiento de la ateroesclerosis.
Begum-Haque et al. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis
Karampoor et al. Maraviroc attenuates the pathogenesis of experimental autoimmune encephalitis
Meng et al. Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells
CA2815542C (en) Use of a spironolactone-based composition that exhibits an inhibitory action on t-lymphocyte activation which is useful for preventing and/or treating multiple sclerosis
Williams et al. Increased limb involvement in murine collagen‐induced arthritis following treatment with anti‐interferon‐gamma
Fang et al. Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats
Yang et al. Periplocoside A ameliorated type II collagen-induced arthritis in mice via regulation of the balance of Th17/Treg cells
Kizelsztein et al. Oral administration of triptolide ameliorates the clinical signs of experimental autoimmune encephalomyelitis (EAE) by induction of HSP70 and stabilization of NF-κB/IκBα transcriptional complex
Bonamigo et al. Neutrophilic dermatoses: part I
Petković et al. Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis
EP2922545B1 (en) Saquinavir-no for immunomodulation
JP2008533107A (ja) 自己免疫疾患および/または移植拒絶反応の予防および/または治療における5’−メチルチオアデノシン(mta)の使用
US20230404980A1 (en) Methods of treating spondyloarthritis or symptoms thereof
Conforti et al. Specific and long-lasting suppression of rat adjuvant arthritis by low-dose Mycobacterium butyricum
HK1212895B (en) Saquinavir-no for immunomodulation
ES2257666T3 (es) Uso de (3-(2-etilfenil)-5-metoxifenil)-1h-(1,2,4)-triazol para el tratamiento de enfermedades autoinmunes.
CN116509873B (zh) 卡铂在制备预防或治疗多发性硬化症药物中的应用
EP3621628A1 (en) Method for treating multiple sclerosis using arsenic trioxide
CN116999479B (zh) 一种大花红景天提取物的应用
Du Growth Hormone Releasing Hormone (GHRH) Signaling Regulates Ocular Inflammation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150518

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid